Universal Prime Editing Therapeutic Strategy for RyR1-Related Myopathies: A Protective Mutation Rescues Leaky RyR1 Channel
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26072835 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Kelly Godbout und 12 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Medicine Department, Laval University, Quebec, QC G1V 0A6, Canada. Hauptthemen laut MEDLINE: Ryanodine Receptor Calcium Release Channel, Gene Editing, Muscular Diseases, Mutation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RYR-1 Foundation, RYR1 Foundation, Fonds de recherche du Québec—Santé (FRQS) scholarship.
Abstract (Originalsprache)
RyR1-related myopathies (RyR1-RMs) include a wide range of genetic disorders that result from mutations in the RYR1 gene. Pathogenic variants lead to defective intracellular calcium homeostasis and muscle dysfunction. Fixing intracellular calcium leaks by stabilizing the RyR1 calcium channel has been identified as a promising therapeutic target. Gene therapy via prime editing also holds great promise as it can cure diseases by correcting genetic mutations. However, as more than 700 variants have been identified in the RYR1 gene, a universal treatment would be a more suitable solution for patients. Our investigation into the RyR1-S2843A mutation has yielded promising results. Using a calcium leak assay, we determined that the S2843A mutation was protective when combined with pathogenic mutations and significantly reduced the Ca2+ leak of the RyR1 channel. Our study demonstrated that prime editing can efficiently introduce the protective S2843A mutation. In vitro experiments using the RNA electroporation of the prime editing components in human myoblasts achieved a 31% introduction of this mutation. This article lays the foundation for a new therapeutic approach for RyR1-RM, where a unique once-in-a-lifetime prime editing treatment could potentially be universally applied to all patients with a leaky RyR1 channel.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Medicine Department, Laval University, Quebec, QC G1V 0A6, Canada.
- CHU de Québec Research Center-Laval University, Quebec, QC G1V 4G2, Canada.
- Department of Physiology and Cellular Biophysics, Center for Molecular Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
ORCID-Profile: Kelly Godbout, Steven R Reiken, Gabriel Lamothe, Geoffrey Canet, Jacques P Tremblay
Förderung
- RYR-1 Foundation
- RYR1 Foundation
- Fonds de recherche du Québec—Santé (FRQS) scholarship
Zitieren
APA
Godbout, K., Dugas, M., Reiken, S. R., Ramezani, S., Falle, A., Rousseau, J., Wronska, A. E., Lamothe, G., Canet, G., Lu, Y., Planel, E., Marks, A. R., & Tremblay, J. P. (2025). Universal Prime Editing Therapeutic Strategy for RyR1-Related Myopathies: A Protective Mutation Rescues Leaky RyR1 Channel. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26072835
Vancouver
Godbout K, Dugas M, Reiken SR, Ramezani S, Falle A, Rousseau J, et al. Universal Prime Editing Therapeutic Strategy for RyR1-Related Myopathies: A Protective Mutation Rescues Leaky RyR1 Channel. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26072835
BibTeX
@article{Godbout2025,
author = {Godbout, Kelly and Dugas, Mathieu and Reiken, Steven R and Ramezani, Sina and Falle, Alexia and Rousseau, Joël and Wronska, Anetta E and Lamothe, Gabriel and Canet, Geoffrey and Lu, Yaoyao and Planel, Emmanuel and Marks, Andrew R and Tremblay, Jacques P},
title = {Universal Prime Editing Therapeutic Strategy for RyR1-Related Myopathies: A Protective Mutation Rescues Leaky RyR1 Channel},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26072835}
}
EUVIMED